FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to compounds of structural formula (1a) possessing the properties of Syk-kinase inhibitors, pharmaceutically acceptable salts thereof, as well as to a based pharmaceutical composition. In general formula (1a), R4 represents or , R2 is specified in a group consisting of phenyl which can be substituted by one or more identical or different groups R8, (C1-C6) alkyl, and pyridyl can be substituted by one or more identical or different groups R8. R5 represents fluorine; each R6 represents hydrogen. The other radical values are specified in the patent claim.
EFFECT: compounds may be used for treating or preventing the autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematous, as well as multiple sclerosis.
12 cl, 11 ex, 16 dwg, 11 tbl
Title | Year | Author | Number |
---|---|---|---|
2,4-PYRIMIDINE DIAMINE COMPOUNDS AND USE THEREOF | 2008 |
|
RU2493150C2 |
METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES BY MEANS OF 2,4-PYRIMIDINDIAMIN COMPOUNDS | 2003 |
|
RU2376992C2 |
PRODRUGS OF 2,4-PYRIMIDINE DIAMINE COMPOUNDS AND USE THEREOF | 2006 |
|
RU2416616C2 |
MONOMER DERIVATIVES OF GLYCOPEPTIDE ANTIBIOTIC | 2005 |
|
RU2424248C2 |
2,4-PYRIMIDINDIAMINE COMPOUNDS HAVING EFFECT IN CASE OF AUTOIMMUNE DISORDERS | 2004 |
|
RU2356901C2 |
MODIFIED RHODAMINE DYE AND ITS USE IN BIOLOGICAL ANALYSIS | 2019 |
|
RU2809712C2 |
COMPOSITIONS FOR TREATING INFLAMMATION AND METHOD OF TREATING INFLAMMATION | 2010 |
|
RU2543720C2 |
METHOD OF TREATING C3-GLOMERULOPATHY | 2017 |
|
RU2742888C2 |
KINASES MODULATION AND INDICATIONS FOR ITS USE | 2012 |
|
RU2631487C2 |
BICYCLIC COMPOUNDS AS PD1/PD-L1 INTERACTION/ACTIVATION INHIBITORS | 2019 |
|
RU2777980C2 |
Authors
Dates
2013-08-27—Published
2003-07-29—Filed